Clinical Trials Logo

Clinical Trial Summary

The goal of this prospective observational study is to explore the role of the gut microbiome in patients with gallstone disease. The main question[s] it aims to answer are: - if there is a relationship between the gut microbiome and the development of complications associated with gallstone disease (such as pancreatitis and acute cholecystitis) - if there are changes in the gut microbiome following cholecystectomy and the relationship with patient outcomes. Participants will be asked to provide stool samples at fixed time points (recruitment, pre- and post-cholecystectomy if applicable and at 6 months and 3 years. They will also be asked to provide stool samples if they represent to hospital with complications associated with their gallstone disease.


Clinical Trial Description

Background: Gallstone disease affects 10-15% of people in the United Kingdom (UK) and over 65,000 patients undergoing cholecystectomy each year, costing the National Health Service (NHS) over 110 million. There is increasing evidence suggesting differences in the gut microbiome of patients with gallstone disease compared to those without (including reduced diversity, decreased prevalence of beneficial and increased prevalence of pathogenic bacteria) but there are only a handful of small scale studies exploring the development of gallstone disease complications and patient outcomes to date. Hypothesis and Objectives: This pilot study aims to understand the profile of the gut microbiome in adult patients diagnosed with gallstone disease and its relationship with patient outcomes including: Patients who develop complications of gallstone disease(including but not limited to biliary colic, cholangitis, cholecystitis, pancreatitis and gallstone ileus) following diagnosis and Patients who develop post-operative complications including short (hospital stay, wound healing etc) and intermediate (development of post-cholecystectomy diarrhoea) outcomes. Design and Methods: A prospective cohort design will be used to collect data from 75 adult patients presenting to East Kent University Hospitals NHS Foundation Trust Hospitals with newly diagnosed gallstone disease following confirmatory imaging investigations. Data will be collected from electronic patient records including clinical history and diagnostic investigations, anthropometry, blood and imaging results (if taken as part of routine clinical care) for the initial presentation and subsequent readmissions/planned follow-up timepoints. Stool samples will be collected from patients either during admission or at home at each timepoint. Samples will be returned by post to the research team where they will be stored and analysed. Patients will also be asked to provide a 3 day food diary card Patients will have a sample collected at time of diagnosis and then at 6 monthly intervals whilst awaiting cholecystectomy. A pre-operative sample will be required within 6 weeks of any surgical intervention. Following cholecystectomy an immediate post-operative sample (within the first week) will be collected as well as a sample at 6 months. Clinical and Scientific Impact: At least 20% of those patients awaiting cholecystectomy experience complications, costing the NHS over £25 million per year. Therefore, there is a huge need to understand mechanisms behind the development of complications and to reduce the symptom burden for patients as well as the financial burden for the NHS. This study is the crucial first step in identifying differences in the gut microbiome between patients who experience complications (both pre and post-op) and those who do not. Once differences are discovered the next step will be to use the information discovered to determine interventions to reduce the development of these complications. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05732480
Study type Observational
Source East Kent Hospitals University NHS Foundation Trust
Contact Charlotte Burford
Phone +44 1227 766877
Email charlotte.burford1@nhs.net
Status Recruiting
Phase
Start date May 30, 2023
Completion date November 13, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT03609944 - SpHincterotomy for Acute Recurrent Pancreatitis N/A
Not yet recruiting NCT04652271 - International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
Completed NCT01441492 - Pancreas Resection With and Without Drains N/A
Recruiting NCT02196935 - Los Angeles Prospective GI Biliary and EUS Series
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01545167 - The North American Pancreatitis Study N/A
Completed NCT04168801 - Early Oral Refeeding in Mild Acute Pancreatitis N/A
Recruiting NCT03334708 - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Completed NCT01824186 - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy N/A
Terminated NCT00428025 - Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients Phase 4
Completed NCT00639314 - Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy N/A
Recruiting NCT00160836 - Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Phase 1
Completed NCT00999232 - Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Phase 4
Completed NCT00121901 - Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis? Phase 3
Terminated NCT00419549 - Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP) Phase 2/Phase 3
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT03601325 - Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
Not yet recruiting NCT06133023 - WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts N/A
Withdrawn NCT02465138 - A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis Phase 4
Recruiting NCT02971475 - ESWL Versus ESWL and Endoscopic Treatment N/A